Data were presented at the 2023 Society for Immunotherapy Annual Meeting.

An estimated survival rate of 71.4% at both 24 and 36 months was observed in patients who received the CAN-2409 regimen together with SoC chemoradiation before surgery, versus only 16.7% survival at 24 and 36 months in patients with SoC chemoradiation before surgery.

5 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with two patients surviving more than 45 months from enrollment. 

Only one patient randomized to control SoC chemotherapy remained alive at the data cut-off (alive at 43 months).

Median overall survival has not yet been reached in patients who received CAN-2409; median overall survival was 12.5 months in the control arm.

The disease course was altered after salvage chemotherapy with improved CA19-9 levels and ongoing survival in the CAN-2409 arm but not in the control arm.

Data showed consistent and robust activation of immune response after dosing with CAN-2409.

CAN-2409 was associated with a favorable tolerability profile.

Candel Therapeutics presented two posters at the 2023 Society for Immunotherapy of Cancer Annual Meeting focused on the enLIGHTEN Discovery Platform.

Price Action: CADL shares are up 20.86% at $0.82 on the last check Monday.